STUDY RESULTS PUBLISHED IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION SHOW AMGEN’S PARSABIV™ (ETELCALCETIDE) SIGNIFICANTLY REDUCED SERUM PARATHYROID HORMONE IN ADULTS WITH SECONDARY HYPERPARATHYROIDISM ON HEMODIALYSIS
Amgen today announced the JAMA publication of findings from three Phase 3 studies of Parsabiv (etelcalcetide), an investigational intravenous calcimimetic agent. The studies evaluated Parsabiv in adults with secondary hyperparathyroidism (sHPT) on hemodialysis and showed that the drug produced statistically significant and clinically meaningful reductions in serum parathyroid hormone (PTH) levels.